A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...
EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to ...
Medpage Today on MSN2d
Online Sellers of Compounded GLP-1s Often Don't Mention RisksHalf of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...
Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback